Ciprofloxacin intratympanic - Otonomy

Drug Profile

Ciprofloxacin intratympanic - Otonomy

Alternative Names: AuriPro™; Ciprofloxacin otic suspension - Otonomy; OTIPRIO; OTO-201

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Otonomy
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Phase III Otitis externa

Most Recent Events

  • 05 Jan 2017 Positive topline efficacy data from a phase III trial in Otitis externa released by Otonomy
  • 01 Dec 2016 Otonomy completes a phase-III trial in Otitis externa (In adolescents, In children, In the elderly, In infants, In adults) in USA and Canada (Intratympanic) (NCT02801370)
  • 04 Oct 2016 Safety and efficacy data from a phase II trial in Otitis media with tympanostomy tubes (In adolescents, In children, In infants) released by Otonomy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top